Idorsia’s daridorexant has experts unsure of its uptake potential due to a lack of...
- Exploring efficiencies from eTMF with Cancer Research UK
- GSK’s Zejula meets primary goal in Phase III ovarian cancer trial
- Trials data suggests Cosentyx from Novartis will change psoriasis market
- Eligibility criteria for clinical trials report challenges in representing LN patients
- Celltrion implements Veeva Vault eTMF to improve visibility into clinical trial activities
Experts doubtful of Idorsia’s daridorexant uptake potential in insomnia
Idorsia’s daridorexant has experts unsure of its uptake potential due to a lack of differentiation from an already approved insomnia therapy with the same mechanism.
Innovation Pharmaceuticals doses first cohort in oral brilacidin trial
Innovation Pharmaceuticals has completed dosing of the first cohort of subjects in its Phase I trial of oral brilacidin.
Neuroptika enrols first patient for dry eye disease trial
Neuroptika has enrolled the first patient in a Phase II clinical trial of NRO-1 for the treatment of dry eye disease.
BioTheryX initiates patient dosing in trial of BTX-A51 for AML
BioTheryX has initiated patient dosing in a Phase I study of BTX-A51 for the treatment of relapsed/refractory acute myeloid leukaemia (AML).
BerGenBio reports positive results from first stage of NSCLC study
Norwegian biopharmaceutical company BerGenBio has reported positive results from the first stage of a Phase II trial (BGBC008) assessing the efficacy of a combination in treating non-small cell lung cancer (NSCLC).
Euan MacDonald Centre launches motor neurone disease trials in UK
The Euan MacDonald Centre at the University of Edinburgh has launched a clinical drug trial for Motor Neurone Disease (MND).
Tolero Pharmaceuticals doses first patient in Phase II Zella 202 study
Tolero Pharmaceuticals has dosed the first patient in a Phase II Zella 202 study of investigational agent alvocidib.
Roivant Sciences launches Lokavant for clinical trial monitoring
Roivant Sciences has launched Lokavant, a technology company to offer real-time and anticipatory clinical trial monitoring to study sponsors and contract research organisations (CROs).
Genome & Company, Merck and Pfizer sign clinical trial agreement
Genome & Company, Merck and Pfizer have signed a clinical trial collaboration and supply agreement to evaluate GEN-001 therapy in oncology indications as part of Phase I/Ib clinical trial.